Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences discrete and related tax charges (benefits) ($M) ($M)
Form 8-K GAAP to Non-GAAP Reconciliation
Latest, FY2025
353
Period ended Dec 31, 2025
Change on a year earlier
+45.3%
243 in FY2024
History
7 years
Since FY2018
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Discrete and related tax charges (benefits) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 353 | +45.3% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2024 | Dec 31, 2024 | 243 | -174.5% | Form 8-K (exhibit991earningspressrel.htm, filed 2026-02-10) ↗ |
| FY2023 | Dec 31, 2023 | -326 | -286.3% | Form 8-K (exhibit991earningspressrel.htm, filed 2025-02-11) ↗ |
| FY2022 | Dec 31, 2022 | 175 | -34.5% | Form 8-K (exhibit991earningspressrel.htm, filed 2024-02-06) ↗ |
| FY2021 | Dec 31, 2021 | 267 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2023-02-02) ↗ |
| FY2019 | Dec 31, 2019 | -1,240 | -310.9% | Form 8-K (exhibit991earningspres.htm, filed 2020-02-04) ↗ |
| FY2018 | Dec 31, 2018 | 588 | – | Form 8-K (exhibit991earningspres.htm, filed 2020-02-04) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Discrete and related tax charges (benefits) ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/ng_adj_discrete_tax
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.